For Research Use Only

CD40L/CD154 Monoclonal antibody

Catalog Number:66502-1-lg 4 Publications




Basic Information	Catalog Number: 66502-1-Ig	GenBank Accession Nu BC071754	mber:	Purification Method: Protein A purification
	Size: 1000 μg/ml	GenelD (NCBI): 959		CloneNo.: 1E6D10
	Source: Mouse	UNIPROT ID: P29965		Recommended Dilutions: WB 1:1000-1:6000
	lsotype: IgG2a	Full Name: CD40 ligand		
	Immunogen Catalog Number: AG24941	Calculated MW: 261 aa, 29 kDa		
		Observed MW: 30 kDa		
Applications	Tested Applications:	Positive Controls:		
	WB, ELISA WB : Jurkat cells, human peripheral blood platele Cited Applications: IHC, IF			
	Species Specificity: Human, rat			
	Cited Species: human			
Background Information	The CD40 ligand (CD40L, TRAP, CD154), a member of the TNF superfamily of ligands, is expressed as either a 33-kc transmembrane homologue or 18-kd soluble form (sCD154). CD40L is primarily expressed on activated CD4+ T cell and on a small proportion of CD8+ T cells and platelets. It binds to CD40 on antigen-presenting cells (APC), which leads to many effects depending on the target cell type. Recent studies have suggested that CD40/CD40L interactions regulate oxidative stress and affect various signaling pathways in both the immunological and the cardiovascular systems. The CD40/CD40L system is also involved in tumorigenesis. Its expression is tightly regulated, and abnormal levels of CD40L are associated with the pathogenesis of atheromatous plaque destabilization and thrombotic events. Multiple mutations in CD40LG gene have been identified that are associate with hyper-IgM immunodeficiency syndrome type 1.			
	cardiovascular systems. The CD40 regulated, and abnormal levels o destabilization and thrombotic ev	D/CD40L system is also invo f CD40L are associated with vents. Multiple mutations in	the pathogen	igenesis. Its expression is tightly esis of atheromatous plaque
Notable Publications	cardiovascular systems. The CD40 regulated, and abnormal levels o destabilization and thrombotic ev	D/CD40L system is also invo f CD40L are associated with vents. Multiple mutations in	the pathogen CD40LG gene	igenesis. Its expression is tightly esis of atheromatous plaque
Notable Publications	cardiovascular systems. The CD44 regulated, and abnormal levels o destabilization and thrombotic ev with hyper-IgM immunodeficienc	D/CD40L system is also invo f CD40L are associated with rents. Multiple mutations in y syndrome type 1.	the pathogen CD40LG gene	igenesis. Its expression is tightly esis of atheromatous plaque have been identified that are associat
Notable Publications	cardiovascular systems. The CD44 regulated, and abnormal levels o destabilization and thrombotic ev with hyper-IgM immunodeficience	D/CD40L system is also invo f CD40L are associated with rents. Multiple mutations in y syndrome type 1. Pubmed ID Journa 36128805 Thyroi	the pathogen CD40LG gene	igenesis. Its expression is tightly esis of atheromatous plaque have been identified that are associat Application
Notable Publications	cardiovascular systems. The CD44 regulated, and abnormal levels o destabilization and thrombotic ev with hyper-IgM immunodeficienc Author YuanPing Hai	D/CD40L system is also invo FCD40L are associated with rents. Multiple mutations in y syndrome type 1. Pubmed ID Journal 36128805 Thyroi 31358479 Pathol	the pathogen CD40LG gene al	igenesis. Its expression is tightly esis of atheromatous plaque have been identified that are associat Application IHC

For technical support and original validation data for this product please contact:T: 4006900926E: Proteintech-CN@ptglab.comW: ptgcn.com

This product is exclusively available under Proteintech Group brand and is not available to purchase from any other manufacturer.

Selected Validation Data



Jurkat cells were subjected to SDS PAGE followed by western blot with 66502-1-1g (CD40L/CD154 antibody) at dilution of 1:3000 incubated at room temperature for 1.5 hours.